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Introduction: Optic neuritis, although uncommon, can be the initial presentation of Sjögren’s syndrome. Coexisting
Sjögren’s syndrome has also been reported with neuromyelitis optica spectrum disorder. This case report highlights
the association between the two diseases and the importance of rheumatological and neurological evaluations in
patients with such diagnoses. Distinction of neuromyelitis optica with coexisting connective tissue disease has both
prognostic and therapeutic significance for the patient.
Case presentation: We report a case of a 56-year-old Chinese woman who presented with bilateral asymmetric
visual loss secondary to optic neuritis. She was subsequently found to be seropositive for neuromyelitis optica
immunoglobulin G (NMO-IgG) (anti-aquaporin-4 antibody) and was diagnosed with neuromyelitis optica spectrum
disorder. She also fulfilled the international criteria for Sjögren’s syndrome. Despite initial high dose
immunosuppressive therapy, she failed to regain vision in one eye.
Conclusion: Patients presenting with optic neuritis and severe visual loss should be screened for neuromyelitis
optica and treated appropriately. Neuromyelitis optica has been associated with systemic autoimmune diseases, in
particular Sjögren’s syndrome, and current evidence indicates that they are two distinct entities. We recommend
that both diagnoses be considered in cases of optic neuritis with severe visual loss.Introduction
Optic neuritis (ON), although uncommon, can be the
initial presentation of Sjögren’s syndrome (SS) [1]. Coex-
isting SS has also been reported in 2% to 30% of patients
with neuromyelitis optica (NMO) [2]. NMO is an in-
flammatory demyelinating disorder of the central ner-
vous system (CNS) characterized by recurrent attacks of
ON and longitudinally extensive transverse myelitis
(LETM) distinct from multiple sclerosis. The discovery
of neuromyelitis optica immunoglobulin G (NMO-IgG)
(anti-aquaporin-4 antibody) and its specificity and sensi-
tivity for NMO has led to its incorporation in the diag-
nostic criteria for NMO. In addition, incomplete forms
of NMO (recurrent ON, LETM) and seropositivity for
NMO-IgG predicts increased risk of progression to full
spectrum NMO, resulting in the designations of these* Correspondence: petrina_tan@ttsh.com.sg
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reproduction in any medium, provided the orconditions as neuromyelitis optica spectrum disorder
(NMOSD) [3]. In this article, we present a patient with
ON who was found to have both primary SS and NMO-
IgG seropositivity, suggestive of NMOSD and review the
recent literature concerning the overlap between pri-
mary SS and NMOSD.Case presentation
A 56-year-old Chinese woman with no previous history
of ON, myelitis or comorbidities, complained of five
days of right-sided headache and progressive visual loss
initially only affecting the right eye but involving the left
on the fifth day. The best-corrected visual acuity of her
right eye at presentation was light perception and 6/7.5
on the left. There was right relative afferent pupillary de-
fect with right disc swelling. The left disc was normal.
Automated perimetry (24–2 threshold, Swedish Inter-
active Threshold Algorithm-standard strategy, Zeiss Carl
Opthalmic Systems-Humphrey Division, Dublin, CA )
could not be done in the patient’s right eye. The test in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ability indices-fixation losses: seven out of 16, false positive
errors: 12%, false negative errors: 6%). A detailed ophthal-
mic examination was performed which included slit lamp
examination of the anterior segment, dilated fundal exam-
ination, intraocular pressure measurement as well as fluor-
escein staining for corneal abnormalities. The ocular
examination was negative for punctate epithelial erosions,
uveitis, pars planitis or retinal vasculitis. There was no
clinical evidence of transverse myelitis, and the patient
declined spinal imaging due to financial constraints. Sero-
logical investigations revealed raised levels of the following
autoimmune antibodies: anti-nuclear antibody, rheuma-
toid factor, anti-Ro antibody as well as NMO-IgG anti-
body. Neuroimaging showed swelling, edema and
enhancement of the orbital segment of the right optic
nerve with marked enhancement and stranding in the
intraconal fat. There was also enhancement of the left
optic sheath and intraconal fat posterior to the globe. No
periventricular white matter plaques were found (Figure 1).Figure 1 Magnetic resonance imaging. (a) Coronal post-
gadolinium fat-saturated T1-weighted image shows enhancement
and stranding in the intraconal fat bilaterally, worse on the right. The
right optic nerve enhances (arrow head) along with enhancement of
the optic sheath. Left perineural enhancement posterior to the
globe is also present, as indicated by the arrow. (b) Axial post-
gadolinium fat-saturated T1-weighted image demonstrated the
marked enhancement in the right intraconal fat.A spinal tap showed normal levels of protein and inflam-
matory cells and oligoclonal bands were absent.
The patient had sicca symptoms for 12 years and the
result of her Schirmer’s test was less than five mm in
both eyes; thus fulfilling the international criteria for
diagnosis of SS.
A diagnosis of NMOSD and primary SS was made.
The patient was started on intravenous methylpredniso-
lone (one mg/kg body weight/day) for five days. As there
was no improvement in the vision of the patient’s right
eye, plasmapheresis was initiated for the patient on the
sixth day. Despite undergoing four cycles of plasma
exchange, vision in the patient’s right eye was unchanged
and the visual acuity of her left eye was 6/7.5. The right
disc showed resolution of disc swelling after three
months with subsequent temporal pallor.
Discussion
This patient’s severe visual loss and degree of intraconal
fat stranding was atypical for demyelinating ON or mul-
tiple sclerosis. She did not have any atherosclerotic risk
factors or elevated levels of erythrocyte sedimentation
rate to suggest non-arteritic and arteritic ischemic optic
neuropathy respectively. The severe asymmetric bilateral
optic neuropathy prompted a search for NMO and asso-
ciated systemic autoimmune diseases such as SS.
CNS involvement in patients with Sjögren’s syndrome
is much less common than peripheral nervous system
involvement and ranges from 2% to 25% among patients
[4,5]. Delalande et al. reviewed the neurologic manifesta-
tions in 82 patients with Sjögren’s syndrome and found
that 13 out of 82 (16%) of patients had visual loss sec-
ondary to ON [1]. In another study by Gono et al., three
of 17 (18%) primary Sjögren’s syndrome patients had
ON [5].
NMO is characterized by significant morbidity in more
than 90% of cases and more than half of the affected
patients will be unable to ambulate without assistance
and/or be functionally blind by five years [6].
An association between NMO, NMOSD and systemic
autoimmune disease has been reported in the literature.
To date, 26 cases of overlap SS and NMO have been
identified [6]. Present studies indicate that ON in
patients with SS who are seropositive for NMO-IgG sig-
nifies the coexistence of two autoimmune diseases rather
than a secondary vasculitic complication of the systemic
disease. Pittock et al. studied NMO or NMOSD patients
who may or may not have overlap SS or systemic lupus
erythematosus (SLE) disease and compared them with a
control group of SS and/or SLE patients [7]. NMO-IgG
was detected only in patients with NMO or NMOSD
with or without SS or SLE and was consistently negative
in the controls. Jarius et al. also studied serum samples
from 109 patients with established or possible systemic
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NMO-IgG [8]. They found that NMO-IgG was present
only in patients with neurological manifestations consist-
ent with NMO, NMOSD, recurrent ON or LETM.
Patients with other neurological manifestations were
seronegative. Furthermore, NMO-IgG serum titres in
patients with NMOSD and systemic autoimmune dis-
ease did not differ significantly from those in a group of
unselected control patients with NMOSD but no sys-
temic autoimmune disease. The above studies support
the concept of NMO-IgG being involved in the patho-
genesis of these neurological diseases and argue against
it being part of the polyclonal B cell activation found in
systemic autoimmune disease.
There is no current published literature regarding
screening for SS in patients with NMO. However,
Sánchez-Guerrero et al. [9] assessed the validity of sev-
eral screening tests (European questionnaire for sicca
symptoms [10], Schirmer’s test, and wafer test [11]) in a
group of 336 ambulatory patients with chronic diseases.
They found that the combined use of a model consisting
of the European questionnaire with at least one affirma-
tive answer, a positive result for Schirmer’s test of less
than five mm in five minutes, and positive wafer test
results had the best performance in terms of prediction
for SS with a likelihood ratio of 9:4. Given the suitability,
ease of administration, low cost and minimal discomfort
of the tests, they recommended their use in parallel to
identify SS in ambulatory patients with chronic diseases.
The availability and use of these tests may vary among
different institutional practices; however, it is useful to
keep in mind these tests when faced with NMO patients
with possible SS.
There are therapeutic implications of the diagnosis of
NMO and the interrelationships between NMO and/or
NMOSD and systemic autoimmune disease. Recognition
of the distinct entity of NMO and/or NMOSD from mul-
tiple sclerosis (MS) is important because treatment recom-
mended for MS-like ON is not applicable. Patients with
NMO-IgG seropositivity have been known to have a high
risk of relapse at 50% or greater, and may need mainten-
ance therapy with azathioprine for a minimum of five years
[12]. Our patient was advised on long-term immunosup-
pression with azathioprine; however, she declined treat-
ment due to financial issues. She has remained relapse-free
for the past 22 months. It is possible that control of auto-
immune disease may be beneficial for the treatment of
NMOSD. Although treatment strategies for NMO and/or
NMOSD and systemic autoimmune disease are similar and
may overlap, care must be taken when treatment involves
use of biologic agents targeting tumor necrosis factor and
its receptors because there have been reports of associated
CNS demyelinating events. Their specific effects on NMO
and/or NMOSD are still unknown.Conclusion
Current literature suggests NMO as a distinct entity from
MS requiring different treatment modalities; as such,
patients presenting with ON and severe visual loss should
be screened for NMO and treated appropriately. Less
commonly, ON may be the initial presentation of SS.
Rheumatologic evaluation should be undertaken in
patients with evidence of clinical and serological auto-
immunity. NMO has been associated with systemic auto-
immune diseases, in particular SS, and current evidence
indicates that they are two distinct entities. Further studies
are required to better understand the impact of these sys-
temic diseases and their treatment on the morbidity of
NMO and NMOSD.
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